Clinical Trial Update: Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacodynamics of SEL-037 (Pegsiticase) in patients with gout and elevated uric acid; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• SEL-037 (Pegsiticase) (Pegsiticase)

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Gout | Phase 1 | Status: COMPLETED